Plain-English translation of NCT06710418 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
When you receive chemotherapy or a stem cell transplant for acute leukemia, your body often can't make enough red blood cells, and you need transfusions to help you feel better and stay safe. This study is testing two different strategies for when to give these transfusions: waiting until your hemoglobin (a measure of red blood cells) drops to 7, or giving transfusions when it drops to 9. The goal is to figure out which approach helps you maintain the best quality of life and physical function during your recovery.
Doctors don't yet know the best timing for red blood cell transfusions in leukemia patients—giving them too often might cause problems, but waiting too long might make you feel sicker or weaker. This study will help doctors understand which approach works best for keeping you healthy and active during treatment.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive blood transfusions at one of two different hemoglobin thresholds—either when your level drops to 7 or to 9—starting the day after your chemotherapy or stem cell transplant ends and continuing for up to 42 days. You'll have regular blood draws to monitor your levels, and the study team will follow your progress for 7 days after the treatment period, then periodically for up to 5 years. During this time, you'll answer questions about how you're feeling and how well you're able to do daily activities.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States